McGuff Pharmaceuticals, Inc. Announces FDA Approval for Hydroxyprogesterone Caproate Injection, USP

McGuff Pharmaceuticals, Inc. (MPI), a California based pharmaceutical manufacturer has received an approval from the FDA for an abbreviated new drug application (ANDA) for Hydroxyprogesterone Caproate Injection USP, 250 mg/mL (1.25 g/5 mL vials).
 
SANTA ANA, Calif. - Oct. 2, 2015 - PRLog -- SANTA ANA, California - McGuff Pharmaceuticals, Inc.  (MPI), a California based pharmaceutical manufacturer has received an approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA) for Hydroxyprogesterone Caproate Injection USP, 250 mg/mL (1.25 g/5 mL vials).

The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL formerly produced by Bristol Myers Squibb.  MPI’s Hydroxyprogesterone Caproate Injection is the current reference listed drug (RLD) for Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL.

Ronald M. McGuff, President and CEO of the Company, commented "This goal was achieved in-house by multidisciplinary teams.  I appreciate and thank each employee for their hard work, dedication and diligence to achieve this significant goal.  HPC represents our first U.S. generic approval in a pipeline that includes generic and new drug products.”  Damon Jones, Vice President of Operations for MPI, noted, “We are very excited to continue to move HPC to commercial launch and provide patient access to this important product.”

MPI’s expected commercial launch is 2016.

About McGuff Pharmaceuticals, Inc.

McGuff Pharmaceuticals is a U.S. based FDA registered manufacturer of investigational and commercial sterile drug products.  McGuff also has proven expertise in obtaining and maintaining national and international drug approvals.

About McGuff Companies

The McGuff family of companies is veteran owned and privately held.  McGuff provides commercial pharmaceuticals, compounded drugs, medical products and contract services used by leading healthcare organizations and professionals.

Corporate Headquarters

·         McGuff Company, Inc. – Medical Products Distribution Center

Subsidiaries:

·         McGuff Pharmaceuticals, Inc. – Commercial drug manufacturing

·         McGuff Medical Canada, Inc. – Medical products distribution

·         McGuff Compounding Pharmacy Services, Inc. – Pharmacy and Compounded drugs

For more information:
McGuff Website - http://www.mcguff.com/
FDA ANDA Approval - http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2...
Hydroxyprogesterone Insert - http://www.mcguffpharmaceuticals.com/images/MD381-0051-Hydroxyprogesterone-Insert%20_v6.pdf

Media Contact
Damon Jones, Vice President Operations
***@mcguff.com
800-603-4795 extension 500
End
Source: » Follow
Email:***@mcguff.com
Posted By:***@mcguff.com Email Verified
Tags:Pharmaceuticals, New Drug Products, Fda Approval
Industry:Health
Location:Santa Ana - California - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Oct 02, 2015
McGuff Pharmaceuticals, Inc. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share